|
Vaughn M. Kailian was named Chairman of the Board of Cerimon Pharmaceuticals, Inc., in May, 2005. Additionally, Mr. Kailian serves as General Partner of MPM Capital. Mr. Kailian previously served as Vice Chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc., and was head of the Millennium commercial organization, where he oversaw the integration of the COR Therapeutics, Inc. (COR) commercial organization, expanded the cardiovascular sales effort and led the establishment of the Millennium commercial group, which successfully launched VELCADE. Prior to joining Millennium, Mr. Kailian served from 1990 until 2002 as CEO, President, and Director of COR. He became the CEO of COR shortly after the company was founded, took the company public in 1991, raised almost $1 billion in public market capital, and led the merger with Millennium in 2002. Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing, and sales positions at Marion Merrell Dow, Inc., and its predecessor companies, including President and General Manager, Merrell Dow USA, and Corporate Vice President of Global Commercial Development, Marion Merrell Dow, Inc. He is the Chairman of the Board of ViaCell, Inc. (Nasdaq: VIAC), Elixir Pharmaceuticals, Inc., and Ikaria, Inc. He is also a Director of NicOx, S.A., and Windhover Information, Inc. Mr. Kailian is currently a member of the Board of BIO Ventures for Global Health and the Pharmaceutical Foundation Advisory Council at the University of Texas at Austin. Mr. Kailian earned his BA degree at Tufts University. | 